Financing led by premier psychedelics focused investment fund Negev Capital
VANCOUVER, BC, July 19, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it intends to complete, subject to regulatory approval, a non-brokered private placement for gross proceeds of up to C$2,000,000 (the "Offering"). The Offering will be led by Negev Capital, a psychedelic medical intervention investment fund.
Read more at newswire.ca